Perspective Therapeutics (Perspective Therapeutics) Valuation Rank

View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Perspective Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Perspective Therapeutics (Perspective Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

AAJ:Germany

Address

350 Hills Street, Suite 106, Richland, WA, USA, 99354

Website

https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

Executives

Williamson Robert F Iii	director	140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann	officer: Chief Medical Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt	officer: Chief Financial Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor	director, officer: CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin	officer: Controller/Prin Fin&Acct Offic	350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale	director	8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick	director	9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann	director	3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon	officer: VP of Sales & Marketing	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline	officer: Dir. of Operations, Secretary	350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter	officer: VP of Human Resources	350 HILLS STREET SUITE 106, RICHLAND WA 99354